FIELD: biochemistry and enzymology.
SUBSTANCE: preparation of amorphous HMG-KoA reductase inhibitor with specified particle size comprises dissolving HMG-KoA reductase inhibitor in hydroxyl-containing solvent and removing solvent via freeze drying.
EFFECT: provided preparation of amorphous HMG-KoA reductase inhibitor using procedure, which can be implemented in industrial scale.
4 cl, 2 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF AMORPHOUS CALCIUM ATORVASTATIN OBTAINING | 2005 |
|
RU2330840C1 |
| FORM VI OF ATORVASTATIN CALCIUM AND ITS HYDRATES | 2002 |
|
RU2294924C2 |
| ARTERIOSCLEROSIS AND XANTHOMA TREATMENT | 1996 |
|
RU2158607C2 |
| NITROOXYDERIVATIVES OF FLUVASTATIN, PRAVASTATIN, CERIVASTATIN, ATOVASTATIN AND ROSUVASTATIN AS CHOLESTEROL-REDUCING AGENTS WITH IMPROVED ANTI-INFLAMMATORY, ANTITHROMBOTIC, ANTI-THROMBOCYTIC ACTIVITY | 2004 |
|
RU2362770C2 |
| PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF LIPID METABOLISM DISORDER | 2001 |
|
RU2246302C2 |
| CRYSTALLINE FORMS VI AND VII OF ATORVASTATIN CALCIUM SALT | 2002 |
|
RU2304139C2 |
| METHOD OF PREPARING AMORPHOUS ATORVASTATINE | 2000 |
|
RU2247113C2 |
| AMORPHOUS CALCIUM ATORVASTATINE PREPARATION METHOD | 2000 |
|
RU2255932C2 |
| CRYSTAL FORM OF PRAVASTATINE SODIUM SALT | 2000 |
|
RU2247711C2 |
| PHARMACEUTICAL COMPOSITION OF STATINS WITH PREBIOTIC FOR THERAPY OF HYPERCHOLESTEREMIA AND HYPERLIPIDEMIA | 2014 |
|
RU2591079C2 |
